おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Vedere Bio ll
company
About
Vedere Bio is developing gene therapy products to restore functional vision to patients who have suffered vision loss.
- 1 - 10
Highlights
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $77M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jun 1, 2019
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Vedere is developing cutting-edge gene therapy products to restore functional vision to patients who have suffered vision loss from Inherited Retinal Degenerations (IRDs), as well as other causes of both genetic and non-genetic vision loss. While the vast majority of ocular gene therapies only limit the rate of inevitable vision loss, we aim to restore lost vision regardless of a patient’s underlying genetics or their stage of disease.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$98M
Vedere Bio ll has raised a total of
$98M
in funding over 2 rounds. Their latest funding was raised on
May 18, 2021 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 18, 2021 | Series A | $77M | 1 | — | — | Detail |
| Jun 1, 2019 | Series A | $21M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
Vedere Bio ll is funded by 2 investors.
Retinal Degeneration Fund
and Foundation Fighting Blindness
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Retinal Degeneration Fund
|
— | Series A |
Foundation Fighting Blindness
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
